SCHEMBL9950343

SCHEMBL9950343

COC(=O)c1cccc(-c2cnnc(Cl)c2)c1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 1/20 0.70
GABRB3 P28472 1/20 0.70
GABRA5 P31644 1/20 0.70
GABRA3 P34903 1/20 0.70
CDK8 P49336 1/20 0.54
NEK1 Q96PY6 5/20 0.50
CA12 O43570 2/20 0.49
CA9 Q16790 2/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
ERN1 O75460 3/20 0.48
AXL P30530 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PLAU P00749 2/20 0.46
CYP19A1 P11511 1/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
GRM5 P41594 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9949738 0.83 GABRG2 (0.70) GABRG2GABRB3GABRA5GABRA3CDK8
SCHEMBL2656140 0.82 GABRG2 (1.00) GABRG2GABRB3GABRA5GABRA3CDK8
SCHEMBL67941 0.80 CA12 (0.68) GABRG2GABRB3GABRA5GABRA3CDK8
SCHEMBL14892283 0.78 CDK8 (0.61) GABRG2GABRB3GABRA5GABRA3CDK8
SCHEMBL5563340 0.78 GABRG2 (0.63) GABRG2GABRB3GABRA5GABRA3CDK8
SCHEMBL27715902 0.78 CA12 (0.71) GABRG2GABRB3GABRA5GABRA3CDK8
SCHEMBL7827008 0.77 PLAU (0.59) GABRG2GABRB3GABRA5GABRA3CDK8
SCHEMBL9949570 0.77 GABRG2 (0.68) GABRG2GABRB3GABRA5GABRA3CDK8
SCHEMBL18961717 0.77 GABRG2 (0.68) GABRG2GABRB3GABRA5GABRA3CDK8
SCHEMBL16094572 0.77 ATM (0.49) GABRG2GABRB3GABRA5GABRA3CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10813930-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2020-10-27 US disclosed
US-10813930-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2020-10-27 US disclosed
US-20190240220-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2019-08-08 US disclosed
US-20190240220-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2019-08-08 US disclosed
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2017-06-15 US disclosed
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2017-06-15 US disclosed
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2017-06-15 US disclosed
US-9533954-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2017-01-03 US disclosed
US-9533954-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2017-01-03 US disclosed
US-20140243308-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2014-08-28 US disclosed
US-20140243308-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2014-08-28 US disclosed
US-20140243308-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2014-08-28 US disclosed
US-8754114-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2014-06-17 US disclosed
US-8754114-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2014-06-17 US disclosed
US-8754114-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2014-06-17 US disclosed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 US disclosed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 US disclosed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 US disclosed
WO-2012088266-A2 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190240220-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 GABRG2 465/4885GABRB3 701/4885GABRA5 257/4885
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 GABRG2 465/4885GABRB3 701/4885GABRA5 257/4885
US-10813930-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 FGFR3, FGFR4, FGFR2 GABRG2 465/4885GABRB3 701/4885GABRA5 257/4885
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 GABRG2 465/4885GABRB3 701/4885GABRA5 257/4885
US-20140243308-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 GABRG2 465/4885GABRB3 701/4885GABRA5 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.